Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Cryogenic Solutions Inc. (CYGS) -- Ignore unavailable to you. Want to Upgrade?

To: Big Dog who wrote (1527)	7/21/1998 9:22:00 AM
From: Janice Shell	Read Replies (4) \| Respond to of 4028

What is fuelling the stock is the CYGS technology. What's fueling the stock is massive hype. As for the "technology", well, gee, I'd really like to know more about that mysterious nameless "inventor" in a "private lab" somewhere in Kansas. And I'd also like to know why this company appears not actually to have an address, but only a MailBoxes Etc. drop. And as previously noted, the frozen embryos fiasco scarcely instills confidence. Here's another old press piece sent to me by a kind lurker. Whatever happened to this acquisition, anybody know? No mention of it at the company website. amcity.com Jennifer Darwin July 22, 1996 c 1996, Houston Business Journal Cryogenic Solutions acquires Physical Therapy in stock deal Cryogenic Solutions Inc. has purchased Houston-based Physical Therapy Associates for 1.5 million shares of restricted stock valued at roughly $750,000. Cryogenic Solutions is a controversial local company involved in freezing aborted fetuses for implantation at a later date. Cryogenic President Dell Gibson says the purchase of Physical Therapy represents the first income for the fledging biotech company. Physical Therapy, which will operate as a wholly-owned subsidiary, has been in business for 35 years and has annual revenues of $750,000, Gibson says. "A little revenue won't hurt," Gibson says. "It'll help us push forward with the research." Cryogenic's main research involves looking for a way to reanimate a fetus once it has been frozen. The technology focuses on returning cells to their early stages of development and then manipulating them to develop into different types of cells. Gibson claims that the company has discovered a new application during the research process that could treat nerve and brain damage using a patient's own cells. "We have stumbled across a way to process normal tissue back to its most primitive stages so that it has the same therapeutic qualities that have been demonstrated with fetal tissue, particularly in the area of repairing nerve damage," Gibson claims. The combination of the companies makes sense, Gibson says, because 70 percent of Physical Therapy's patients suffer from nerve damage. The group and its owner, Michael Walters, see this technique as a way to take care of their patients in the future, he says. Physical Therapy will retain its management and remain separate from Cryogenic, other than to use its technology once it's developed, Gibson says. Gibson has come under fire from anti-abortion groups and members of the scientific communities for his work (see "Fetus freezing firm spawns controversy," March 8). Investors have been cool toward Cryogenic since the company went public in February in a move to raise capital for research. The stock is currently trading on Nasdaq for about 50 cents a share.